CD40L is necessary for the priming of effector cells for lymphocytic and granulomatous experimental autoimmune thyroiditis

Citation
Ke. Peterson et H. Braley-mullen, CD40L is necessary for the priming of effector cells for lymphocytic and granulomatous experimental autoimmune thyroiditis, J AUTOIMMUN, 12(1), 1999, pp. 1-12
Citations number
39
Categorie Soggetti
Immunology
Journal title
JOURNAL OF AUTOIMMUNITY
ISSN journal
08968411 → ACNP
Volume
12
Issue
1
Year of publication
1999
Pages
1 - 12
Database
ISI
SICI code
0896-8411(199902)12:1<1:CINFTP>2.0.ZU;2-0
Abstract
The interaction of CD40 on antigen presenting cells (APC) with CD40L on mou se thyroglobulin (MTg)-specific T cells may deliver an essential signal for the development of CD4(+) experimental autoimmune thyroiditis (EAT) effect or cells and anti-MTg producing B cells. To determine the requirement for C D40-CD40L interactions in G-EAT, donor mice were injected with an anti-CD40 L monoclonal antibody (mAb) on days -1, 0, and +1 relative to immunization with MTg and adjuvant. Recipients of spleen cells from MTg primed donor mic e injected with anti-CD40L did not develop EAT, while spleen cells from sim ilarly immunized hamster Ig-treated donors transferred severe G-EAT. Althou gh the decreased EAT severity was accompanied by increased IL-4 mRNA expres sion by CD4(+) T cells from anti-CD40L-treated donors, the increased IL-4 w as not necessary for suppression of EAT, since anti-CD40L treatment prevent ed EAT in IL-4-deficient mice. Addition of MTg-primed B cells during in vit ro activation of spleen cells from anti-CD40L-treated donors did not induce EAT in recipients, suggesting that anti-CD40L suppresses EAT by preventing the sensitization of EAT effector cells. Addition of anti-CD40L during in vitro activation of MTg-primed spleen cells or treatment of recipients with anti-CD40L had no effect on EAT severity, indicating that CD40-CD40L inter actions are not required after EAT effector cells are primed to MTg. (C) 19 99 Academic Press.